UK trimethoprim switch
This article was originally published in The Tan Sheet
Executive Summary
UK's Medicines and Healthcare products Regulatory Agency (MHRA) seeks comments on the Prescription Only Medication (POM) to Pharmacy (P) reclassification of Alpharma Limited's Cysticlear (trimethoprim) 200 mg tablets for treatment of urinary tract infections. The request is not surprising in light of the UK's current switch environment; McNeil Europe VP-R&D Stephen Mann recently predicted trimethoprim would "almost certainly go" POM to P by the end of the year (1"The Tan Sheet," July 4, 2005, p. 11). MHRA asks that comments be submitted by Aug. 16...